Gold­man Sach­s' Ankang Li heads to biotech Terns as new CFO; SV re­cruits new part­ner for De­men­tia Dis­cov­ery Fund

→ Fresh off a NASH deal with French drug­mak­er Gen­fit, Terns Phar­ma has ap­point­ed Ankang Li as CFO. The Chi­nese biotech scooped Li from Gold­man Sachs, where he led high pro­file biotech IPOs as ex­ec­u­tive di­rec­tor of health­care in­vest­ment bank­ing. A law school grad­u­ate with a back­ground in bio­med­ical re­search — his ca­reer has tak­en him to Salk In­sti­tute and Mer­ck’s Asia Pa­cif­ic in­no­va­tion hub — Li will hold ex­ten­sive re­spon­si­bil­i­ties in cor­po­rate fi­nanc­ing and busi­ness de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.